Department of Oncology, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Cytotherapy. 2012 Apr;14(4):483-93. doi: 10.3109/14653249.2011.649185. Epub 2012 Jan 25.
The aim of this study was to evaluate the efficacy and safety of cytokine-induced killer (CIK) cell therapy for solid carcinomas.
We performed a computerized search of phase II/III clinical trial databases of CIK cell-based therapy using a combination of the terms 'cytokine-induced killer cells', 'tumor' and 'cancer'.
Treatment with CIK cells was associated with a significantly improved half-year survival (P = 0.003), 1-year survival (P = 0.0005), 2-year survival (P < 0.01) and mean survival time (MST) (P < 0.001). Patients in the CIK group showed a prolonged half-year progression-free survival (PFS) (P < 0.01), 1-year PFS (P < 0.01) and median time to progression (MTTP) (P < 0.001). A favored disease control rate (DCR) was observed in patients receiving CIK cell therapy, while the objective response rate (ORR) was not altered (P = 0.05) compared with the non-CIK group (P = 0.007). CIK cell therapy could also reduce the adverse effects of grade III and IV leukopenia caused by chemotherapy (P = 0.002) and diminish hepatitis B virus (HBV)-DNA content (P < 0.01). However, the incidence of fever in the CIK therapy group was significantly higher than in the non-CIK group (P = 0.02). The percentage of CD3(+), CD4(+), CD4(+)CD8(+), CD3(-) CD56(+) and CD3(+) CD56(+) T-lymphocyte subsets in the peripheral blood of cancer patients was significantly increased, whereas the percentage of CD8(+) T-lymphocyte cells was significantly decreased in the CIK group compared with the non-CIK group (P < 0.01).
CIK cell therapy has demonstrated a significant superiority in prolonging the MST, PFS, DCR and quality of life (QoL) of patients.
本研究旨在评估细胞因子诱导的杀伤（CIK）细胞疗法治疗实体瘤的疗效和安全性。
我们使用细胞因子诱导的杀伤细胞、肿瘤和癌症等术语的组合，对基于 CIK 细胞的治疗的 II/III 期临床试验数据库进行了计算机检索。
CIK 细胞治疗与半年生存率（P = 0.003）、一年生存率（P = 0.0005）、两年生存率（P < 0.01）和平均生存时间（MST）（P < 0.001）的显著提高相关。CIK 组患者的半年无进展生存期（PFS）（P < 0.01）、一年 PFS（P < 0.01）和中位进展时间（MTTP）（P < 0.001）均延长。与非 CIK 组相比，CIK 细胞治疗组患者的疾病控制率（DCR）更高（P = 0.007），而客观缓解率（ORR）未改变（P = 0.05）。CIK 细胞治疗还可以降低化疗引起的 III 级和 IV 级白细胞减少的不良影响（P = 0.002），并降低乙型肝炎病毒（HBV）-DNA 含量（P < 0.01）。然而，CIK 治疗组发热的发生率明显高于非 CIK 组（P = 0.02）。与非 CIK 组相比，癌症患者外周血中的 CD3(+)、CD4(+)、CD4(+)CD8(+)、CD3(-)CD56(+)和 CD3(+)CD56(+)T 淋巴细胞亚群的百分比明显增加，而 CD8(+)T 淋巴细胞细胞的百分比明显减少（P < 0.01）。
CIK 细胞治疗在延长 MST、PFS、DCR 和生活质量（QoL）方面显示出显著优势。
